



## **Press release**

### **Number of shares and votes in Orexo**

**Uppsala, Sweden – August 30, 2013** - The number of shares and votes in Orexo AB has changed as a result of the conversion of convertible bonds subscribed for by Novo A/S and the exercise of warrants.

Today, the last trading day of the month, there are in total 32,532,858 shares and votes in the company.

#### **For further information, please contact:**

Henrik Juuel, EVP and Chief Financial Officer

Tel: +46 (0)722-20 94 77, E-mail: [henrik.juuel@orexo.com](mailto:henrik.juuel@orexo.com)

#### **About Orexo**

Orexo AB is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. Orexo's expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue generating US and EU approved products currently marketed under licence and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharma companies. Orexo, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo please visit [www.orexo.com](http://www.orexo.com)

*Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 4:30 pm CET on August 30, 2013.*